Gambaran Umum
Reviva Pharmaceuticals adalah perusahaan farmasi tahap klinis yang mengembangkan terapi untuk mengatasi kebutuhan medis yang belum terpenuhi di bidang sistem saraf pusat, kardiovaskular, metabolik, dan penyakit peradangan. Fokus utama Reviva adalah mengembangkan kandidat produk unggulannya, RP5063 (brilaroxazine), untuk pengobatan skizofrenia, gangguan bipolar, dan gangguan depresi mayor.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai operating income untuk Reviva Pharmaceuticals Holdings, Inc. per 2025 Jun 30 adalah -27.36 MM.
- Nilai net income untuk Reviva Pharmaceuticals Holdings, Inc. per 2025 Jun 30 adalah -27.11 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | -27.36 | -27.11 | |
2025-03-31 | -29.41 | -28.92 | |
2024-12-31 | -30.80 | -29.92 | |
2024-09-30 | -34.13 | -33.01 | |
2024-06-30 | -37.24 | -35.99 | |
2024-03-31 | -40.44 | -39.84 | |
2023-12-31 | -39.50 | -39.26 | |
2023-09-30 | -41.58 | -41.95 | |
2023-06-30 | -33.58 | -34.12 | |
2023-03-31 | -27.76 | -27.75 | |
2022-12-31 | -28.23 | -28.26 | |
2022-09-30 | -20.50 | -19.91 | |
2022-06-30 | -19.41 | -18.67 | |
2022-03-31 | -15.68 | -14.94 | |
2021-12-31 | -10.10 | -8.52 | |
2021-09-30 | -6.67 | -6.36 | |
2021-06-30 | -4.70 | -4.74 | |
2021-03-31 | -3.69 | -3.98 | |
2020-12-31 | -2.43 | -3.78 | |
2020-09-30 | -1.95 | -2.33 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk Reviva Pharmaceuticals Holdings, Inc. pada 2025 Jun 30 adalah -0.64.
- laba per saham yang terdilusi untuk Reviva Pharmaceuticals Holdings, Inc. pada 2025 Jun 30 adalah -0.64.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | -0.64 | -0.64 |
2025-03-31 | -0.76 | -0.76 |
2024-12-31 | -0.90 | |
2024-09-30 | -1.09 | -1.09 |
2024-06-30 | -1.29 | -1.29 |
2024-03-31 | -1.54 | -1.54 |
2023-12-31 | -1.65 | |
2023-09-30 | -1.87 | -1.87 |
2023-06-30 | -1.60 | -1.60 |
2023-03-31 | -1.36 | -1.36 |
2022-12-31 | -1.45 | |
2022-09-30 | -1.07 | -1.07 |
2022-06-30 | -1.01 | -1.01 |
2022-03-31 | -0.87 | -0.87 |
2021-12-31 | -0.58 | |
2021-09-30 | -0.57 | -0.57 |
2021-06-30 | -0.66 | -0.66 |
2021-03-31 | -0.85 | -0.85 |
2020-12-31 | -1.24 | |
2020-09-30 | -0.13 | -0.13 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Reviva Pharmaceuticals Holdings, Inc. per 2025 Jun 30 adalah -26.55 MM.
- Nilai kas dari aktivitas pendanaan untuk Reviva Pharmaceuticals Holdings, Inc. per 2025 Jun 30 adalah 30.73 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -26.55 | 30.73 | |
2025-03-31 | -30.01 | 23.33 | |
2024-12-31 | -33.54 | 23.65 | |
2024-09-30 | -33.32 | 33.91 | |
2024-06-30 | -35.26 | 30.28 | |
2024-03-31 | -32.10 | 32.82 | |
2023-12-31 | -28.32 | 33.17 | |
2023-09-30 | -24.14 | 5.92 | |
2023-06-30 | -21.96 | 13.69 | |
2023-03-31 | -20.65 | 8.48 | |
2022-12-31 | -18.96 | 7.79 | |
2022-09-30 | -18.17 | 7.87 | |
2022-06-30 | -16.48 | 0.10 | |
2022-03-31 | -13.82 | 31.60 | |
2021-12-31 | -10.67 | 31.60 | |
2021-09-30 | -9.70 | 42.84 | |
2021-06-30 | -8.11 | 43.71 | |
2021-03-31 | -7.12 | 12.60 | |
2020-12-31 | -4.07 | 12.83 | |
2020-09-30 | -1.14 | 1.48 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/e untuk Reviva Pharmaceuticals Holdings, Inc. pada 2025 Jun 30 adalah -0.61.
- p/libro untuk Reviva Pharmaceuticals Holdings, Inc. pada 2025 Jun 30 adalah -3.99.
- p/tbv untuk Reviva Pharmaceuticals Holdings, Inc. pada 2025 Jun 30 adalah -3.99.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | -0.61 | -3.99 | -3.99 |
2025-03-31 | -4.71 | -4.71 | |
2024-12-31 | -6.06 | -6.06 | |
2024-09-30 | -1.24 | -7.39 | -7.39 |
2024-06-30 | -0.96 | -28.36 | -28.36 |
2024-03-31 | -12.78 | -12.78 | |
2023-12-31 | -3.81 | -16.84 | -16.84 |
2023-09-30 | -3.68 | 69.58 | 69.58 |
2023-06-30 | -4.99 | 20.33 | 20.33 |
2023-03-31 | -3.52 | 6.95 | |
2022-12-31 | 4.26 | 4.26 | |
2022-09-30 | 2.01 | 2.01 | |
2022-06-30 | -1.20 | 0.84 | 0.84 |
2022-03-31 | -4.35 | 1.29 | 1.29 |
2021-12-31 | -6.35 | 1.25 | 1.25 |
2021-09-30 | -11.47 | 1.57 | 1.57 |
2021-06-30 | |||
2021-03-31 | -4.84 | 4.27 | 4.27 |
2020-12-31 | -5.10 | 3.53 | 3.53 |
2020-09-30 | -16.28 | -4.39 | -4.39 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Reviva Pharmaceuticals Holdings, Inc. pada 2025 Jun 30 adalah -2.27.
- EBIT (3 tahun) / EV untuk Reviva Pharmaceuticals Holdings, Inc. pada 2025 Jun 30 adalah -2.51.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -2.27 | -2.51 |
2025-03-31 | -0.79 | -0.77 |
2024-12-31 | -0.60 | -0.58 |
2024-09-30 | -0.93 | -0.81 |
2024-06-30 | -1.50 | -0.98 |
2024-03-31 | -0.36 | -0.23 |
2023-12-31 | -0.27 | -0.15 |
2023-09-30 | -0.30 | -0.18 |
2023-06-30 | -0.22 | -0.15 |
2023-03-31 | -0.36 | -0.21 |
2022-12-31 | -0.31 | -0.15 |
2022-09-30 | -1.45 | -0.71 |
2022-06-30 | 2.68 | 1.29 |
2022-03-31 | -1.15 | -0.62 |
2021-12-31 | -0.92 | -0.53 |
2021-09-30 | -0.26 | -0.13 |
2021-06-30 | ||
2021-03-31 | -0.08 | -0.05 |
2020-12-31 | -0.09 | -0.05 |
2020-09-30 | -0.03 | -0.01 |
Efektivitas Manajemen
- roa untuk Reviva Pharmaceuticals Holdings, Inc. pada 2025 Jun 30 adalah -3.59.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -3.59 | ||||
2025-03-31 | -2.45 | ||||
2024-12-31 | -1.39 | -5.77 | |||
2024-09-30 | -6.68 | ||||
2024-06-30 | -3.09 | -6.89 | |||
2024-03-31 | -1.99 | -3.06 | |||
2023-12-31 | -1.57 | -1.85 | |||
2023-09-30 | -1.49 | -1.91 | -16.64 | -4.48 | -11.91 |
2023-06-30 | -1.14 | -1.47 | -13.40 | -3.61 | -9.60 |
2023-03-31 | -0.96 | -1.14 | -4.08 | -2.10 | -3.57 |
2022-12-31 | -0.59 | -0.62 | -0.98 | -0.51 | -0.89 |
2022-09-30 | -0.55 | -0.58 | -0.98 | -0.51 | -0.89 |
2022-06-30 | -0.41 | -0.43 | -1.16 | -1.02 | -1.03 |
2022-03-31 | -1.28 | -1.89 | -0.70 | 0.83 | -0.65 |
2021-12-31 | -0.73 | -0.86 | -0.30 | 0.73 | -0.29 |
2021-09-30 | -3.12 | -0.20 | 1.03 | -0.23 | |
2021-06-30 | -23.25 | -0.14 | 1.03 | -0.23 | |
2021-03-31 | -20.24 | -0.43 | 0.59 | -0.73 | |
2020-12-31 | -1,455.15 | -0.31 | 0.71 | -0.30 | |
2020-09-30 |
Gross Margins
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1742927 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |